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Abstract
Background
Multiple sclerosis (MS) is a neurodegenerative, autoimmune disease of the central nervous
system. Genome-wide association studies (GWAS) have identified over hundred polymor-
phisms with modest individual effects in MS susceptibility and they have confirmed the main
individual effect of the Major Histocompatibility Complex. Additional risk loci with immuno-
logically relevant genes were found significantly overrepresented. Nonetheless, it is
accepted that most of the genetic architecture underlying susceptibility to the disease
remains to be defined. Candidate association studies of the leukocyte immunoglobulin-like
receptor LILRA3 gene in MS have been repeatedly reported with inconsistent results.
Objectives
In an attempt to shed some light on these controversial findings, a combined analysis
was performed including the previously published datasets and three newly genotyped
cohorts. Both wild-type and deleted LILRA3 alleles were discriminated in a single-tube PCR
amplification and the resulting products were visualized by their different electrophoretic
mobilities.
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Results and Conclusion
Overall, this meta-analysis involved 3200 MS patients and 3069 matched healthy controls
and it did not evidence significant association of the LILRA3 deletion [carriers of LILRA3
deletion: p = 0.25, OR (95% CI) = 1.07 (0.95–1.19)], even after stratification by gender and
the HLA-DRB1*15:01 risk allele.
Introduction
Multiple sclerosis (MS), a disease of the central nervous system involving chronic inflamma-
tion, axonal damage and demyelination, is likely caused by the interplay of genetic and envi-
ronmental risk factors. The class II HLA-DRB115:01 allele has been described as the main
genetic susceptibility factor for the disease[1], although other immunological relevant genes
have been also recently associated with MS predisposition [2].
Leukocyte immunoglobulin-like receptors (LILRs), also known as immunoglobulin-like
transcripts (ILTs) or monocyte inhibitory receptors (MIRs), are broadly expressed on myeloid
and lymphoid cells and play an important role in modulating innate and adaptive immune
responses [3]. LILRA3 is a soluble protein of the LILR family that contains four Ig-like domains
(D1, D2, D3 and D4) and acts as a soluble receptor for certain class I Major Histocompatibility
Complex (MHC) antigens [4].
Members of the LILR gene family map to the leukocyte receptor complex on chromosome
19q13.4, a region that encodes at least 24 members of the immunoglobulin superfamily [5].
Reportedly, chromosome 19q13 is one of the genomic regions that exhibits clustering of sus-
ceptibility loci in several autoimmune diseases including MS [6, 7]. However, genome-wide
association studies (GWAS) performed to date have not been able to detect any signal with sig-
nificant association in this region when considering MS risk [8, 9]. GWAS benefit of a high
throughput technology based on genotyping a growing number of single-nucleotide polymor-
phisms (SNPs), even over a million. Nonetheless, this is a limited strategy to detect any other
kind of genetic variants such as deletions, unless they show high linkage disequilibrium with a
SNP. An unprecedented advance unraveling the genetic architecture of complex diseases has
been driven by these genome-wide studies, but a high percentage of the heritability of these dis-
orders still remains unidentified [10].
The LILRA3 gene exhibits a 6.7kb deletion comprising the first 6 of a total of 7 exons, result-
ing in a “null allele” because it removes all the regions coding Ig-like domains of the protein
[11–13]. At present, little is known about its role in the immune system. The LILRA3 gene has
been associated with increased susceptibility to Sjögren's syndrome and to some subpheno-
types of systemic lupus erythematosus [14, 15]. Increased levels of the soluble LILRA3 protein
have been found in patients with rheumatoid arthritis [16]. Moreover, a study published by Du
et al.[17] provided evidence for the functional LILRA3 allele as a genetic risk factor only for
male patients with rheumatoid arthritis. These data point to a potential genetic background
shared by different autoimmune diseases, as described by some authors[18].
The association of the LILRA3 deletion with MS susceptibility has been repeatedly studied
[6, 19–21] yielding inconclusive results, some of them reporting significant effects while others
being unable to confirm the association. Therefore, we aimed to perform a new analysis trying
to ascertain the effect of the LILRA3 deletion on MS risk in people with European ancestry. To
do so, all previously published datasets and three newly genotyped cohorts were included in a
meta-analysis. Further, we investigated the epistatic interaction between LILRA3 and the
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classical MS risk factor HLA-DRB115:01, considering also the effect of gender previously
described as a determinant in the LILRA3 effect.
Material and Methods
Patients
A total of 1932 relapsing-remitting and secondary progressive (11% of total) MS patients of
Spanish ancestry and 1599 ethnically matched controls was consecutively recruited from the
following Spanish Hospitals: H. Clínico San Carlos and H. Ramón y Cajal, fromMadrid, Cen-
tral Spain (1422 patients and 841 controls); H. Virgen Macarena (Sevilla) and H. Virgen de las
Nieves (Granada) from Andalusia, South of Spain (236 patients and 443 controls); and H. Vall
d´Hebron (Catalonia), Northeast of Spain (274 patients and 315 controls). Both clinical forms
are considered two stages of the same disease, to which we will refer here as relapse-onset MS
(R-MS). Patients were diagnosed on the basis of McDonald criteria [22] and were recruited
after written informed consent. The Ethics Committee of the Hospital Clínico San Carlos
(CEIC- Comité Etico de Investigación Clínica) approved this study.
Genotyping
The presence/ absence of the LILRA3 deletion in our samples was studied as previously
described [20]. Briefly, both wild-type and deleted LILRA3 alleles were discriminated in a
single-tube PCR amplification and the resulting products were visualized by their different
electrophoretic mobility in regular agarose gels.
Literature search and data abstraction
Genetic association studies investigating the role of LILRA3 on MS susceptibility in European
populations were identified by two independent researchers using the following terms:
“LILRA3 or ILT6 or 19q13” and “multiple sclerosis” in NCBI's PubMed, Web of Science,
Embase, Scopus and Google Scholar databases and by inspecting cross-references in related
publications. All the articles published before June 2015 were included. No discrepancies
between researchers were found. After review of 36 full-text articles, four of them published in
peer-reviewed journals and including genotyping data from five populations were selected for
meta-analysis, and the other 32 articles were excluded (see S1 Table, S1 Checklist and S1
PRISMA Checklist.). Raw data were requested to the corresponding author when not included
in the study.
Meta-analysis
Meta-analyses were performed with the published and the newly generated datasets, based on
the previously reported strategy followed by Lill et al. [23], Fig 1. The Cochran-Mantel-Haens-
zel method implemented in Review Manager (RevMan) version 5.0 (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2008) was used to calculate combined odds
ratios (OR) and 95% confidence intervals (CI). P-values<0.05 were considered statistically sig-
nificant. The Der Simonian and Laird random effects model was used according to the results
of the tests of heterogeneity. A sensitivity analysis was performed to test the relative influence
of each study: studies were sequentially dropped, and the effect on the change in the overall
degree of heterogeneity was quantified with the I2 statistic.
LILRA3Deletion on Multiple Sclerosis Risk
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Fig 1. Flowchart of literature search, data extraction and association analysis of LILRA3 andMS risk.
doi:10.1371/journal.pone.0134414.g001
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Statistical analysis
Hardy-Weinberg proportions (HWE) were tested in controls. Statistical analyses were per-
formed by using the SPSS 17.0 package (SPSS Inc, Chicago, IL). Allelic and genotypic fre-
quency comparisons were analyzed using the χ2 test of a Fisher exact test (when expected
values were below 5). Odds ratio (ORs) were calculated and their 95% CIs were estimated with
the Cornfield method. Power calculations were performed by using the statistical software
package Statcal Epi Info v.6.
Results
Association of the LILRA3 deletion with R-MS susceptibility
Four previously published reports have studied the association of the LILRA3 deletion with MS
susceptibility risk in five individual datasets (Fig 1). Meta-analysis across these published data-
sets yielded a statistically significant effect in carriers of the LILRA3 deletion [p = 0.03; OR
(95% CI) = 1.19 (1.02–1.40)], with modest evidence of heterogeneity (I2 = 25%). Subsequently,
a combined analysis of the previously published datasets adding the data of the three newly
genotyped independent cohorts was performed. Overall, this meta-analysis including 3200 MS
patients and 3069 matched healthy controls did not reveal significant evidence for association
and yielded an effect size close to one [Fig 2, carriers of LILRA3 deletion: p = 0.25, OR (95%
CI) = 1.07 (0.95–1.19)] with moderate evidence for heterogeneity (I2 = 32%). The number of
individuals included would allow the detection of an effect with OR> 1.17, with a statistical
power over 80%. A further sensitivity analysis was performed in this study, which provided I2
values ranging from 2% to 41%: the analysis excluding the dataset “2009-Spain (Madrid)” led
to the lowest heterogeneity, and again statistical significance was not observed (p = 0.49).
Analysis of the epistatic interaction between the LILRA3 deletion and the
HLA-DRB1*15:01 allele
To check for an epistatic interaction between the LILRA3 deletion and the classical MS risk fac-
tor HLA-DRB115:01, a meta-analysis of those datasets including both variants was performed
(Fig 3). The meta-analysis did not evidence any significant epistatic interaction when these two
genetic factors were considered [p = 0.36, OR (95% CI) = 1.09 (0.91–1.30)]. Conversely, to
ascertain whether a possible effect of the LILRA3 deletion might be restricted to subjects lack-
ing the HLA-DRB115:01 allele, the same analysis was performed in this group of patients, but
a significant difference was not observed [p = 0.74, OR (95% CI) = 1.03 (0.88–1.20)].
Fig 2. Meta-analysis assessing the association of LILRA3 deletion with MS risk in populations of European descent. Forest plot of random effects
with study-specific ORs (squares) and 95%CIs (lines) calculated for each individual dataset. Pooled OR (diamond) and 95%CI were calculated combining
all datasets.
doi:10.1371/journal.pone.0134414.g002
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Analysis of the epistatic interaction between the LILRA3 deletion and
HLA-DRB1*15:01 allele after gender-stratification
Further analysis was performed stratifying by gender the LILRA3 deletion/ HLA-DRB115:01
double-positive subjects and again, a significant difference was not detected [Fig 4, p = 0.39,
OR (95% CI) = 1.09 (0.90–1.31)] with total homogeneity of strata (I2 = 0%). In addition, sepa-
rated analyses in male and female groups were also performed, with similar results observed in
both cases [male: p = 0.76, OR (95% CI) = 1.05 (0.76–1.47) and female: p = 0.40, OR (95% CI)
= 1.10 (0.88–1.38)]. Neither significant evidence of sex-bias was observed in carriers of the
LILRA3 deletion lackingHLA-DRB115:01 (data not shown).
Discussion
The role of genetics in MS susceptibility is highly accepted and broadly described in the litera-
ture. At present, the greatest advances in the study of this genetic component have been
achieved through GWAS, which analyze thousands of patients and ethnically matched controls
searching for evidences to explain MS pathogenesis. However, this kind of studies does not
explore genetic variants other than SNPs and the heritability underlying this and other com-
plex diseases persists partially unexplained.
Previously reported studies tried to evaluate the influence of the LILRA3 deletion on MS
risk; however, their results were not fully concordant and it was difficult to draw a firm
Fig 3. Random effects meta-analysis including association studies of the LILRA3 deletion with MS risk inHLA-DRB1*15:01 carriers from
populations of European descent. Study-specific ORs (squares) and 95%CIs (lines) were calculated for each individual dataset. Pooled OR and 95%CI
were calculated combining all datasets. Del+/15:01+: carrier of LILRA3 deletion andHLA-DRB1*15:01 allele.
doi:10.1371/journal.pone.0134414.g003
Fig 4. Random effects meta-analysis of the association studies of the LILRA3 deletion with MS risk inHLA-DRB1*15:01 carriers from populations
of European descent stratified by gender. Study-specific ORs (squares) and 95%CIs (lines) were calculated for each individual dataset. Pooled OR and
95%CI were calculated combining all datasets. Del+/15:01+: carrier of both LILRA3 gene deletion andHLA-DRB1*15:01 allele, M: male, F: female.
doi:10.1371/journal.pone.0134414.g004
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conclusion regarding the impact of this gene on MS. Two studies performed in German [21]
and Spanish populations [20] showed a significant association of the LILRA3 deletion with
R-MS, with the strongest association found in the Spanish study. A MS cohort of French origin
showed a high LILRA3-deletion frequency (46.1%), but the study included no matched French
healthy controls[21], and it has not been included in our meta-analysis. Conversely, two studies
performed in Finnish [6] and Polish populations [19] could not replicate the association.
Therefore, a risk of publication bias does not seem to be present in the study of this gene. The
meta-analysis combining the mentioned cohorts evidenced a statistically significant association
of LILRA3 deletion with MS risk [p = 0.03, OR (95% CI) = 1.19 (1.02–1.40)], with modest evi-
dence of heterogeneity (I2 = 25%).
Considering that small sample sizes might explain the inconsistent results observed in the
different reports, we aimed to ascertain the influence of the LILRA3 deletion on R-MS suscepti-
bility by studying this association in a large number of individuals from three different Spanish
locations (Barcelona, Madrid and Andalusia) and performing a meta-analysis with the avail-
able data. Overall, our study with 6380 individuals (3257 MS patients and 3123 healthy
matched controls) did not reveal any significant difference when the distribution of the
LILRA3 deletion in MS patients and controls was compared [p = 0.25, OR (95% CI) = 1.07
(0.95–1.19)], albeit in the context of a moderate evidence of heterogeneity (I2 = 32%). Substan-
tial attenuation of the latter was achieved after the sensitivity analysis, which showed that the
exclusion of the “2009-Spain (Madrid)” cohort reported by Ordonez et al. [20] led to a lower
heterogeneity in the overall meta-analysis, still lacking significant association (p = 0.49). Inter-
estingly, the maximum reduction of heterogeneity was reached when the study with the highest
impact on MS risk was removed from the meta-analysis, raising the possibility that the effect
once observed was driven by a strong signal in this cohort. In conclusion, it seems that the
LILRA3 deletion by itself does not alter MS susceptibility.
Additionally, we also considered two other important factors: HLA-DRB115:01 as the main
risk allele described in MS and the putative gender bias,which might underlie the inconsistent
results reported in the different studies. As previously described by Ordonez et al. [20],we
assessed whether there was a synergistic effect betweenHLA-DRB115:01 and the LILRA3 dele-
tion in order to confer MS risk, but no significant epistatic interaction was observed (p = 0.36).
Moreover, to evaluate whether the LILRA3 deletion presented a possible gender bias in MS
risk, as described by Du et al. in rheumatoid arthritis susceptibility [17], the epistatic interac-
tion was also studied after gender stratification. Again, no significant differences were observed
in male or female MS patients (p = 0.76 and p = 0.40, respectively), although two of the initial
datasets were excluded as they lacked both gender- and DRB115:01- detailed information.
Therefore, stratifications considering either theHLA-DRB115:01 allele by itself or including
also gender information did not evidence global association of LILRA3 deletion with MS risk,
demonstrating that a more stringent stratification of patients did not explain previous results.
Some works seemed to support the role of the LILRA3 gene conferring risk to different auto-
immune diseases and this gene would be another example of the well-established concept of
shared genetic background among autoimmune diseases [14, 15, 17]. However, some of those
studies warrant validation in independent cohorts or populations, provided that the studies
including the greatest number of subjects have been performed in Asian populations. The fre-
quency of the 6.7kb deletion differ greatly among ethnic groups, with extremely high values in
Asians (0.56–0.84), and much lower values in Europeans (0.17) or Africans (0.10) [24]. It is
well known that Asian and Caucasian populations show specific risk variants given the differ-
ent genetic drift and the resulting different patterns of linkage disequilibrium (LD). In Asian
populations, one SNP (rs103294) was found in LD (r2 = 0.83) with the LILRA3 deletion and,
therefore, it was selected by Du et al. to study the association of the LILRA3 gene with
LILRA3Deletion on Multiple Sclerosis Risk
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rheumatoid arthritis susceptibility[17]. In Caucasian populations, the LD pattern between the
aforementioned SNP and the LILRA3 deletion has not been formally reported. Nonetheless,
this SNP was included in an analysis of immune-related loci that identified 48 new risk variants
for MS [2]. Although the allelic frequencies of rs103294 and other polymorphisms close to the
LILRA3 gene are similar to that displayed by the LILRA3deletion, no association with either
MS or rheumatoid arthritis, psoriasis, type 1 diabetes or celiac disease risk was identified in this
region, in agreement with the present results.
Our results are also concordant with those found in psoriasis, that reported lack of signifi-
cant association between the LILRA3 deletion and the disease in a European population [25],
although this finding warrants replication as well. All these lines of evidence together indicated
that LILRA3 does not seem to be underlying MS pathogenesis. Understanding the full load of
genetic factors contributing to disease risk has potential for profound improvements in health
care. Yet, the known genetic factors account for only a small portion of the estimated heritabil-
ity of complex phenotypes and every effort to overcome this impasse should be emphasized.
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